First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Saved in:
| Title: | First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. |
|---|---|
| Authors: | Iacovelli, R.1 (AUTHOR) Roberto.iacovelli@policlinicogemelli.it, Ciccarese, C.1 (AUTHOR), Brunelli, M.2 (AUTHOR), Battelli, N.3 (AUTHOR), Buttigliero, C.4 (AUTHOR), Caserta, C.5 (AUTHOR), Buti, S.6,7 (AUTHOR), Santini, D.8,9 (AUTHOR), Carella, C.10 (AUTHOR), Galli, L.11 (AUTHOR), Verri, E.12 (AUTHOR), Ermacora, P.13 (AUTHOR), Merler, S.14 (AUTHOR), Masini, C.15 (AUTHOR), De Vivo, R.16 (AUTHOR), Milesi, L.17 (AUTHOR), Spina, F.18 (AUTHOR), Rizzo, M.19 (AUTHOR), Sperduti, I.20 (AUTHOR), Fornarini, G.1,21 (AUTHOR) |
| Source: | Annals of Oncology. Nov2022, Vol. 33 Issue 11, p1179-1185. 7p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!